Hims & Hers Stock Rallies After Analysts Boost Price Targets

Hims & Hers rebounds over 5% as analysts raise price targets. Key developments suggest potential growth despite risks surrounding semaglutide's availability.

Date: 27-02-2025

AI Rating: 7

Stock Performance and Analyst Ratings
Hims & Hers stock has shown a positive recovery of over 5% mid-week following a decline earlier in the week. This recovery can largely be attributed to several analysts who raised their price targets on the company after its recent drop, which surpassed the S&P 500's flat performance.

Impact of Product Announcement
Investor sentiment deteriorated earlier due to Hims & Hers' announcement regarding the potential halt of sales for its compound versions of semaglutide, a product linked to a current shortage. The FDA has declared this shortage over, causing concerns among investors about the company's future prospects without this popular product. Despite this bearish sentiment, analysts have positively rated the stock, indicating a belief in its growth potential even without semaglutide.

Analyst Insights
TD Cowen's analyst Jonna Kim aggressively raised her price target for Hims & Hers from $28 to $44 per share, maintaining a buy recommendation, which indicates confidence in the stock's future performance. Other analysts from Piper Sandler and Truist also boosted their price targets but adopted a more cautious hold recommendation.

The collective view from analysts suggests that while the loss of semaglutide may impact the company negatively, the innovative nature of Hims & Hers' product offerings will support its growth trajectory. The capital investment made in marketing this product signifies a substantial initial commitment, but its loss must be managed strategically to avoid declines in market perception.

Stocks: HIMS